Does tamoxifen cause cancer in humans?

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 779-792

  Stearns, Vered ^a   Gelmann, Edward P ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; HYDROXYTAMOXIFEN; TAMOXIFEN; TAMOXIFEN CITRATE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CARCINOMA; DNA ADDUCT; DRUG CARCINOGENICITY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; FEMALE; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECOND CANCER; UTERUS BLEEDING;

EID: 0031917523     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.779     Document Type: Review

References (143)

1. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989
2. Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15,1992
3. Nayfield SG, Karp J, Ford LG, et al: Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83:1450-1459, 1991
4. Love RR: Antiestrogen chemoprevention of breast cancer: Critical issues and research. Prev Med 20:64-78, 1991
5. Fisher B, Redmond C: New perspective on cancer of the contralateral breast: A marker for assessing tamoxifen as a preventing agent. J Natl Cancer Inst 83:1278-1280, 1991
6. Jordan VC: The role of tamoxifen in the treatment and prevention of breast cancer. Curr Probl Cancer 16:129-176, 1992
7. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542, 1996
8. Blackburn AM, Amiel SA, Millis RR, et al: Tamoxifen and liver damage. Br Med J 289:288, 1984
9. VanHoof M, Rahier J, Horsmans Y: Tamoxifen-induced steatohepatitis. Ann Intern Med 124:855-856, 1996
10. Love RR, Cameron L, Connell BL, et al: Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 151:1842-1847, 1991
11. Love RR: Tamoxifen therapy in primary breast cancer: Biology, efficacy, and side effects. J Clin Oncol 7:803-815, 1989
12. Fornander T, Rutqvist LE: Adjuvant tamoxifen and second cancers. Lancet 1:616, 1989
13. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537, 1994
14. Andersson M, Storm HH, Mouridsen HT: Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83:1013-1017, 1991
15. Heel RC, Brogden RN, Speight TM, et al: Tamoxifen: A review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs 16:1-24, 1978
16. Kangas L: Agonistic and antagonistic effects of antiestrogens in different target organs. Acta Oncol 31:143-146, 1992
17. Ferrazzi E, Cartei G, Mattarazzo R, et al: Oestrogen-like effect of tamoxifen on vaginal epithelium. Br Med J 1:1351-1352, 1977
18. Boccardo F, Bruzzi P, Rubagotti A, et al: Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 38:281-285, 1981
19. Boccardo F, Guarneri D, Rubagotti A, et al: Endocrine effects of tamoxifen in postmenopausal breast cancer patients. Tumori 70:61-68, 1984
20. Turken S, Siris E, Seldin D, et al: Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 81:1086-1088, 1989
21. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992
22. Love RR, Newcomb PA, Wiebe DA, et al: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82:1327-1332, 1990
23. Schapira DV, Kumar NB, Lyman GH: Serum cholesterol reduction with tamoxifen. Breast Cancer Res Treat 17:3-7, 1990
24. Helgason S, Wilking N, Carlstrom K, et al: A comparative study of the estrogenic effects of tamoxifen and 17 beta-estradiol in postmenopausal women. J Clin Endocrinol Metab 54:404-408, 1982
25. Mani C, Kupfer D: Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: Possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res 51:6052-6058, 1991
26. Mani C, Gelboin HV, Park SS, et al: Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab Dispos 21:645-656, 1993
27. Lim CK, Yuan ZX, Lamb JH, et al: A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis 15:589-593, 1994
28. Phillips DH, Carmichael PL, Hewer A, et al: Activation of tamoxifen and its metabolite alpha-hydroxytamoxifen to DNA-binding products: Comparisons between human, rat and mouse hepatocytes. Carcinogenesis 17:89-94, 1996
29. Purchase IF: Inter-species comparisons of carcinogenicity. Br J Cancer 41:454-468, 1980
30. Gonzalez FJ: Genetic polymorphism and cancer susceptibility: Fourteenth Sapporo Cancer Seminar. Cancer Res 55:710-715, 1995
31. Pathak DN, Bodell WJ: DNA adduct formation by tamoxifen with rat and human liver. Carcinogenesis 15:529-532, 1994
32. Robinson SP, Langan-Fahey SM, Johnson DA, et al: Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 19:36-43, 1991
33. Straub KM, Burlingame AL: Carcinogen binding to DNA. Biomed Mass Spectrom 8:431-435, 1981
34. Hemminki K: DNA adducts, mutations and cancer. Carcinogenesis 14:2007-2012, 1993
35. Santella RM, Yang XY, Hsieh LL, et al: Immunologic methods for the detection of carcinogen adducts in humans. Basic Life Sci 53:33-44, 1990
36. Weston A: Physical methods for the detection of carcinogen-DNA adducts in humans. Mutat Res 288:19-29, 1993
37. Randerath K, Randerath E, Agrawal HP, et al: Postlabeling methods for carcinogen-DNA adduct analysis. Environ Health Perspect 62:57-65, 1985
38. Han XL, Liehr JG: Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52:1360-1363, 1992
39. Hard GC, Iatropoulos MJ, Jordan K, et al: Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl: CD(BR) rats. Cancer Res 53:4534-4541, 1993
40. Carthew P, Martin EA, White IN, et al: Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: Promotion by phenobarbital. Cancer Res 55:544-547, 1995
41. Carthew P, Rich KJ, Martin EA, et al: DNA damage as assessed by 32P-postlabelling in three rat strains exposed to dietary tamoxifen: The relationship between cell proliferation and liver tumour formation. Carcinogenesis 16:1299-1304, 1995
42. White IN, de Matteis F, Davies A, et al: Genotoxic potential of tamoxifen and analogues in female Fischer F349/n rats, DBA/2 and C57BI/6 mice and in human MU-S cells. Carcinogenesis 13:2197-2203, 1992
43. Cai Q, Wei H: In vivo formation of DNA-adducts in mouse skin DNA by tamoxifen. Cancer Lett 92:187-192, 1995
44. Randerath K, Bi J, Mabon N, et al: Strong intensification of mouse hepatic tamoxifen DNA adduct by pretreatment with the sulfotransferase inhibitor and ubiquitous environmental pollutant pentachlorophenol. Carcinogenesis 15:797-800, 1994
45. Randerath K, Moorthy B, Mabon N, et al: Tamoxifen: Evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis 15:2087-2094, 1994
46. Li D, Dragan Y, Jordan VC, et al: Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney and uterus. Cancer Res 57:1438-1441, 1997
47. Poon GK, Walter B, Lonning PE, et al: Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab Dispos 23:377-382, 1995
48. Hemminki K, Widlak P, Hou SM: DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis 16:1661-1664, 1995
49. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 16:1651-1654, 1995
50. Styles JA, Davies A, Lim CK, et al: Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis 15:5-9, 1994
51. Phillips DH, Hewer A, Grover PL, et al: Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients. Carcinogenesis 17:1149-1152, 1996
52. Phillips DH, Potter GA, Horton MN, et al: Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates alpha hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis 15:1487-1492, 1994
53. Potter GA, McCague R, Jarman M: A mechanistic hypothesis for DNA adduct formation by tamoxifen. Carcinogenesis 15:439-442, 1994
54. Phillips DH, Carmichael PL, Hewer A, et al: Alpha-hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res 54:5518-5522, 1994
55. Pathak DN, Pongracz K, Bodell WJ: Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: Comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis 16:11-15, 1995
56. Osborne MR, Hewer A, Hardcastle IR, et al: Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res 56:66-71, 1996
57. Moorthy B, Sriram P, Pathak DN, et al: Tamoxifen metabolic activation: Comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vitro. Cancer Res 56:53-57, 1996
58. Carmichael PL, Ugwumadu AH, Neven P, et al: Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 56:1475-1479, 1996
59. Hemminki K, Rajaniemi H, Lindahl B, et al: Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 56:4374-4377, 1996
60. Sargent LM, Dragan YP, Bahnub N, et al: Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. Cancer Res 54:3357-3360, 1994
61. Sargent LM, Dragan YP, Sattler C, et al: Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats. Carcinogenesis 17:1051-1056, 1996
62. Vancutsem PM, Lazarus P, Williams GM: Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res 54:3864-3867, 1994
63. Davies R, Oreffo VIC, Martin EA, et al: Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats. Cancer Res 57:1288-1293, 1997
64. Williams GM, Iatropoulos MJ, Djordjevic MV, et al: The triphenylethylene drug tamoxifen is a strong liver carcinogen. Carcinogenesis 14:315-317, 1993
65. Greaves P, Goonetilleke R, Nunn G, et al: Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53:3919-3924, 1993
66. Hirsimaki P, Hirsimaki Y, Nieminen L, et al: Tamoxifen induces hepatocellular carcinoma in rat liver: A 1-year study with two antiestrogens. Arch Toxicol 67:49-54, 1993
67. Tucker MJ, Adam HK, Patterson JS: Tamoxifen, in Laurence DR, McLean AEM, Weatherall M (eds): Safety Testing of New Drugs. London, United Kingdom, Academic, pp 125-161, 1984
68. Yager JD, Roebuck BD, Paluszcyk TL, et al: Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase-positive foci in female rats. Carcinogenesis 7:2007-2014, 1986
69. Dragan YP, Fahey S, Street K, et al: Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Res Treat 31:11-25, 1994
70. Ghia M, Mereto E: Induction and promotion of gamma-glutamyltranspeptidase-positive foci in the liver of female rats treated with ethinyl estradiol, clomiphene, tamoxifen and their associations. Cancer Lett 46:195-202, 1989
71. Yager JD, Shi YE: Synthetic estrogens and tamoxifen as promoters of hepatocarcinogenesis. Prev Med 20:27-37, 1991
72. Carthew P, Edwards RE, Nolan BM, et al: Tamoxifen associated uterine pathology in rodents: Relevance to women. Carcinogenesis 17:1577-1582, 1996
73. Mantyla ETE, Karlsson SH, Nieminen LS: Induction of endometrial cancer by tamoxifen in the rat, in Li JJ (ed): Hormonal Carcinogenesis II, Proceedings of an International Symposium. New York, NY, Springer, 1996, pp 442-445
74. Furr BJ, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205, 1984
75. Gottardis MM, Robinson SP, Satyaswaroop PG, et al: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48:812-815, 1988
76. Jordan VC, Gottardis MM, Satyaswaroop PG: Tamoxifen-stimulated growth of human endometrial carcinoma. Ann NY Acad Sci 622:439-446, 1991
77. Anzai Y, Holinka CF, Kuramoto H, et al: Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). Cancer Res 49:2362-2365, 1989
78. Satyaswaroop PG, Zaino RJ, Mortel R: Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 44:4006-4010, 1984
79. Ismail SM: Pathology of endometrium treated with tamoxifen. J Clin Pathol 47:827-833, 1994
80. Neven P, De Muylder X, Van Belle Y, et al: Tamoxifen and the uterus and endometrium. Lancet 1:375-376, 1989
81. Corley D, Rowe J, Curtis MT, et al: Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol 79:111-116, 1992
82. Sismondi P, Biglia N, Volpi E, et al: Tamoxifen and endometrial cancer. Ann NY Acad Sci 734:310-321, 1994
83. Decensi A, Fontana V, Bruno S, et al: Effect of tamoxifen on endometrial proliferation. J Clin Oncol 14:434-440, 1996
84. De Muylder X, Neven P, De Somer M, et al: Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet 36:127-130, 1991
85. Lahti E, Blanco G, Kauppila A, et al: Endometrial changes in postmenopausal breast cancer patients. Obstet Gynecol 81:660-664, 1993
86. Cohen I, Rosen DJ, Shapira J, et al: Endometrial changes with tamoxifen: Comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 52:185-190, 1994
87. Gal D, Kopel S, Bashevkin M, et al: Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer - Preliminary report. Gynecol Oncol 42:120-123, 1991
88. Kedar RP, Bourne TH, Powles TJ, et al: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 343:1318-1321, 1994
89. Silva EG, Tornos CS, Follen-Mitchell M: Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: The effects of tamoxifen. Int J Gynecol Pathol 13:248-258, 1994
90. Barakat RR, Wong G, Curtin JP, et al: Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 55:164-168, 1994
91. MacMahon B, Austin JH: Association of carcinomas of the breast and corpus uteri. Cancer 23:275-280, 1969
92. Harvey EB, Brinton LA: Second cancer following cancer of the breast in Connecticut, 1935-82. Natl Cancer Inst Monogr 68:99-112, 1985
93. Adami HO, Krusemo UB, Bergkvist L, et al: On the age- dependent association between cancer of the breast and of the endometrium. A nationwide cohort study. Br J Cancer 55:77-80, 1987
94. Smith DC, Prentice R, Thompson DJ, et al: Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293:1164-1167, 1975
95. Ziel HK, Finkle WD: Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293:1167-1170, 1975
96. Hoover R, Fraumeni JF, Everson R, et al: Cancer of the uterine corpus after hormonal treatment for breast cancer. Lancet 1:885-887, 1976
97. Killackey MA, Hakes TB, Pierce VK: Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 69:237-238, 1985
98. Hardell L: Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet 2:563, 1988
99. Atlante G, Pozzi M, Vincenzoni C, et al: Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol Oncol 37:378-380, 1990
100. Malfetano JH: Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 39:82-84, 1990
101. Mathew A, Chabon AB, Kabakow B, et al: Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. NY State J Med 90:207-208, 1990
102. Cohen CJ, Rahaman J: Endometrial cancer. Management of high risk and recurrence including the tamoxifen controversy. Cancer 76:2044-2052, 1995
103. Fornander T, Cedermark B, Mattsson A, et al: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 2:117-120, 1989
104. Fornander T, Hellstrom AC, Moberger B: Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 85:1850-1855, 1993
105. Andersson M, Storm HH, Mouridsen HT: Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol 31:259-263, 1992
106. Ryden S, Ferno M, Moller T, et al: Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial. Acta Oncol 31:271-274, 1992
107. Rutqvist LE, Johansson H, Signomklao T, et al: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87:645-651, 1995
108. Fisher B: Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. J Clin Oncol 14:1027-1039, 1996
109. The Nolvadex Adjuvant Trial Organization: Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet 1:836-840, 1985
110. The Nolvadex Adjuvant Trial Organization: Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 57:608-611, 1988
111. Castiglione M, Gelber RD, Goldhirsch A: Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group. J Clin Oncol 8:519-526, 1990
112. Boccardo F, Rubagotti A, Bruzzi P, et al: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: Results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. J Clin Oncol 8:1310-1320, 1990
113. Boccardo F, Rubagotti A, Amoroso D, et al: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. Eur J Cancer 28:673-680, 1992
114. Ribeiro G, Swindell R: The Christie Hospital adjuvant tamoxifen trial - Status at 10 years. Br J Cancer 57:601-603, 1988
115. Ribeiro G, Swindell R: The Christie Hospital adjuvant tamoxifen trial. Monogr Natl Cancer Inst 11:121-125, 1992
116. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 2:171-175, 1987
117. Stewart HJ: The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. Monogr Natl Cancer Inst 11:117-120, 1992
118. Hubay CA, Gordon NH, Pearson OH, et al: Eight-year follow-up of adjuvant therapy for stage II breast cancer. World J Surg 9:738-749, 1985
119. Cummings FJ, Gray R, Tormey DC, et al: Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: Long-term follow-up and causes of death. J Clin Oncol 11:29-35, 1993
120. Powles TJ, Hardy JR, Ashley SE, et al: Chemoprevention of breast cancer. Breast Cancer Res Treat 14:23-31, 1989
121. Powles TJ, Jones AL, Ashley SE, et al: The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31:73-82, 1994
122. Curtis RE, Boice JD, Shriner DA, et al: Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 88:832-834, 1996
123. Hardell L: Pelvic irradiation and tamoxifen as risk factors for carcinoma of corpus uteri. Lancet 2:1432, 1988
124. Hardell L: Tamoxifen as a risk factor for endometrial cancer. Cancer 66:1661, 1990
125. van Leeuwen FE, Benraadt J, Coebergh JW, et al: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448-452, 1994
126. Cook LS, Weiss NS, Schwartz SM, et al: Population-based study of tamoxifen therapy and subsequent ovarian, endometrial and breast cancers. J Natl Cancer Inst 87:1359-1364, 1995
127. Robinson DC, Bloss JD, Schiano MA: A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol Oncol 59:186-190, 1995
128. Sasco AJ, Chaplain G, Amoros E, et al: Endometrial cancer following breast cancer: Effect of tamoxifen and castration by radiotherapy. Epidemiology 7:9-13, 1996
129. Cuenca RE, Giachino J, Arredondo MA, et al: Endometrial carcinoma associated with breast carcinoma: Low incidence with tamoxifen use. Cancer 77:2058-2063, 1996
130. Magriples U, Naftolin F, Schwartz PE, et al: High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11:485-490, 1993
131. Rutqvist LE: Long-term toxicity of tamoxifen. Recent Results Cancer Res 127:257-266, 1993
132. Assikis VJ, Jordan VC: Tamoxifen and endometrial cancer: From experiment to patient. Recent Results Cancer Res 140:61-71, 1996
133. Muhlemann K, Cook LS, Weiss NS: The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamoxifen in 1977. Breast Cancer Res Treat 30:201-204, 1994
134. Vuopala S, Kauppila A, Mikkonen M, et al: Screening of asymptomatic postmenopausal women for gynecological malignancies, with special reference to endometrial sampling methods. Arch Gynecol 231:119-127, 1982
135. Koss LG: Detection of endometrial carcinoma in asymptomatic peri- and postmenopausal women. Acta Cytol 24:492-493, 1980
136. Osmers R, Volksen N, Schauer T: Vaginosonography for early detection of endometrial carcinoma? Lancet 335:1569-1571, 1990
137. Nasri MN, Shepherd JH, Setchell ME, et al: The role of vaginal scan in measurement of endometrial thickness in postmenopausal women. Br J Obstet Gynaecol 98:470-475, 1991
138. Fleischer AC, Cullinan JA, Kepple DM, et al: Conventional and color Doppler transvaginal sonography of pelvic masses: A comparison of relative histologic specificities. J Ultrasound Med 12:705-712, 1993
139. Nasri MN, Coast GJ: Correlation of ultrasound findings and endometrial histopathology in postmenopausal women. Br J Obstet Gynaecol 96:1333-1338, 1989
140. Cohen I, Rosen DJ, Shapira J, et al: Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 100:567-570, 1993
141. Goldstein SR: Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 170:447-451, 1994
142. Neven P, DeMuylder X, VanBelle Y, et al: Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynecol Reprod Biol 35:235-238, 1990
143. Cohen I, Rosen DJ, Tepper R, et al: Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med 12:275-280, 1993